Beyondspring Incis A Clinical Stage Biopharmaceutical Company Based In New Jerseythe Company Is Dedicated To Developing Innovative Therapies Aimed At Improving Clinical Outcomes For Patientsparticularly In The Areas Of Immuno Oncology And Cancer Treatments Beyondspring S Lead Asset Is Plinabulinwhich Is Being Developed As A Direct Anti Cancer Agent And To Prevent Chemotherapy Induced Neutropeniathe Company Also Has Three Preclinical Immuno Oncology Assets In Its Pipelineadditionallybeyondspring Owns Seed Therapeuticswhich Focuses On Targeted Protein Degradation Technology For Drug Discoverywith A Strong Emphasis On Oncology And Neurodegeneration Beyondspring Has Formed Partnerships With Major Pharmaceutical Companiesincluding Eli Lilly And Eisai Coltd To Enhance Its Research And Development Effortsthe Company Is Actively Advancing Its Pipelinewith Plans For Plinabulin To Enter Anti Cancer Registrational Studies And Seed Therapeutics Expected To Begin Clinical Trials With An Oncology Asset In 2025
